Rabeprazole Sodium

雷贝拉唑钠

Report date: 2026/01/06 15:22:08
NME

Base Information

Drug NameRabeprazole Sodium
Drug Alias NameRabelocRabeprazolPariprazoleRabeprazolumRabecure Pack 400 +[21] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProton pump inhibitors
TargetsProton pump
Therapy Area/IndicationsHelicobacter pylori infectionHeartburnDyspepsia +[19] 
Global Approved IndicationsHelicobacter pylori infectionHeartburnStomach Ulcer +[9] 
Approved Indications in ChinaStomach UlcerDuodenal UlcerEsophagitis, Peptic +[4] 
Original Approved Country/TerritoryJapan
Original Approved Date1997/10/14
Country/TerritoryBelgiumBulgariaCanada +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Yizhuang Kangqiao Industrial Investment Fund Partnership Enterprise (Limited Partnership)Beijing Peak Biology Pharmaceuticals Co LtdAvalo Therapeutics Inc +[10] 
Inactive CompaniesUtah State UniversityJanssen-Ortho Inc., CanadaGenuine Research Center, Egypt +[17] 
Active IndicationsHelicobacter pylori infectionHeartburnUlcer +[12] 
Inactive IndicationsDyspepsiaHemorrhageAsthma +[7] 

Other Information

ATC CodeA02BC04
Related LinksWikipediaDrugBankKEGG